Payer News

UnitedHealthcare says IDR awards near 6% of commercial spend in some regions

Source: Becker’s Payer Issues · Elizabeth Casolo · October 14, 2026

Summary published October 19, 2026

Becker’s reports UnitedHealthcare’s regional estimate of arbitration spending and its concerns about rising commercial medical costs.

What did UnitedHealthcare report?

Becker’s Payer Issues reports that CEO Tim Noel told an October 13 earnings call that No Surprises Act arbitration awards can approach 6% of total commercial medical spending in some regions.

Is 6% a national figure?

No. The article attributes the estimate to UnitedHealthcare and limits it to certain regions. It should not be read as a nationwide measure across all insurers or a prediction of individual claim outcomes.

What other cost pressures were discussed?

Noel said commercial medical cost trends were exceeding an initial 11% expectation. Alongside arbitration costs, he cited clinician cost intensity and expensive specialty drugs. He also criticized the conduct of some clinician groups and third-party organizations; those characterizations represent the payer’s position.

Our takeaway for provider teams

This reporting adds a payer perspective to the debate over IDR costs. Regional spending estimates do not establish whether a particular claim is eligible or what it should receive. Keep eligibility review, supporting documentation, and payment follow-up grounded in each claim’s circumstances.